SEARCH

SEARCH BY CITATION

REFERENCES

  • Andrechek ER, Muller WJ. 2000. Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. Breast Cancer Res 2: 149153.
  • Attardi LD, Jacks T. 1999. The role of p53 in tumor suppression: lessons from mouse models. Cell Mol Life Sci 55: 4863.
  • Bennett LM, McAllister KA, Malphurs J, Ward T, Collins NK, Seely JC, Gowen LC, Koller BH, Davis BJ, Wiseman RW. 2000. Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol. Cancer Res 60: 34613469.
  • Cardiff RD, Gumerlock PH, Soong MM, Dandekar S, Barry PA, Young LJT, Myers FJ. 1988. c-H-ras-1 expression in 7,12-dimethylbenzathracene-induced BALB/c mouse mammary hyperplasias and their tumors. Oncogene 3: 205213.
  • Cardiff RD, Moghanaki D, Jensen RA. 2000. Genetically engineered mouse models of mammary intraepithelial neoplasia. J Mammary Gland Biol Neoplasia 5: 421437.
  • Coffey RJ Jr, Meise KS, Matsui Y, Hogan BL, Dempsey PJ, Halter SA. 1994. Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7,12-dimethylbenzanthracene. Cancer Res 54: 16781683.
  • D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK, Golant A, Cardiff RD, Chodosh LA. 2001. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7: 235239.
  • Goepfert TM, McCarthy M, Kittrell FS, Stephens C, Ullrich RL, Brinkley BR, Medina D. 2000. Progesterone facilitates chromosome instability (aneuploidy) in p53 null normal mammary epithelial cells. FASEB J 14: 22212229.
  • Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi S. 1999. Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc Natl Acad Sci USA 96: 25202525.
  • Jerry DJ, Butel JS, Donehower LA, Paulson EJ, Cochran C, Wiseman RW, Medina D. 1994. p53 mutations occur infrequently in 7,12-dimethylbenzanthracene-induced mammary tumors in BALB/c and hemizygous p53 mice. Mol Carcinog 9: 175183.
  • Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ, Butel JS, Medina D. 2000. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene 19: 10521058.
  • Jones JM, Attardi L, Godley LA, Laucirica R, Medina D, Jacks T, Varmus HE, Donehower LA. 1997. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ 8: 829838.
  • Kumar R, Medina D, Sukumar S. 1990. Activation of H-ras oncogenes in preneoplastic mouse mammary tissues. Oncogene 5: 12711277.
  • Kuperwasser C, Hurlburt GD, Kittrell FS, Dickinson ES, Laucirica R, Medina D, Naber SP, Jerry DJ. 2000. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. Am J Pathol 157: 21512159.
  • Li B, Murphy KL, Laucirica R, Kittrell F, Medina D, Rosen JM. 1998. A transgenic mouse model for mammary carcinogenesis. Oncogene 16: 9971007.
  • Liebelt AG, Liebelt RA. 1967. Chemical factors in mammary tumorigenesis. In: Carcinogenesis: a broad critique. Presented at Annual Symposium of Fundamental Cancer Research. Baltimore: Williams & Wilkins. p 315345.
  • Mantel N. 1966. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163170.
  • Medina D. 1971. The effects of hormone stimulation, dose and time of administration on carcinogen-induced tumors from preneoplastic nodule outgrowths. J Natl Cancer Inst 46: 909916.
  • Medina D. 2000. Mouse models for mammary cancer. In: IpMM, AschBB, editors. Methods in mammary gland biology and breast cancer research. New York: Kluwer Academic. p 317.
  • Medina D, Kittrell FS. 1987. Enhancement of tumorigenicity with morphological progression in a BALB/c preneoplastic outgrowth line. J Natl Cancer Inst 79: 569576.
  • Medina D, Stephens LC, Bonilla PJ, Hollmann CA, Schwahn D, Kuperwasser C, Jerry DJ, Butel JS, Meyn RE. 1998. Radiation-induced tumorigenesis in preneoplastic mouse mammary glands in vivo; significance of p53 status and apoptosis. Mol Carcinog 22: 199207.
  • Muller WJ, Neville MC. 2001. Signal transduction in mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia 6: 1150.
  • Murphy KL, Dennis AP, Rosen JM. 2000. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J 14: 22912302.
  • Peto R. 1974. Guidelines in the analysis of tumor rates and death rates in experimental animals. Br J Cancer 29: 101105.
  • Ross RK, Paganini-Hill A, Wan PC, Pike MC. 2000. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92: 328332.
  • Ullrich RL, Bowles ND, Satterfield LC, Davis CM. 1996. Strain-dependent susceptibility to radiation-induced mammary cancer is a result of differences in epithelial cell sensitivity to transformation. Radiat Res 146: 353355.
  • Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. 1994. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369: 669671.
  • Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A, Deng CX. 1999. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22: 10.